Engineered human stomach organoids, transplanted into mice, produced insulin-secreting cells, offering a potential new ...

The company's initial target is immuno-oncology projects but there are plans to expand into autoimmune disease, infectious disease, and more.

Abzena and Mabqi bring together two organizations that are focused on advancing antibody innovation through integration.

Technology opens the door to more accurate preclinical testing, which could enable the development of safer and more effective therapies.

Researchers analyzed the role of NUDT5 and its interaction with other proteins in the folate pathway and in regulating purine synthesis.

CAR T and CAR Treg therapies revolutionize cancer treatment through automation, scalability, and global manufacturing innovation.

The data shows that downregulating PU.1 promotes the expression of immunoregulatory proteins on microglia that help protect cognitive function.

South Rampart Pharma is working to develop an oral small molecule non-opioid pain treatment which has generated early positive clinical data as a therapy for acute and chronic pain, as well as ...

The goal of the project is to develop novel approaches that strengthen and reduce the costs of domestic mAb biomanufacturing to protect against and treat infection by filoviruses.

FDA approved KYGEVVI, the first and only treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients.

Triple therapy approach that hits cancer from multiple angles at once could be a game-changer against breast cancers that no longer respond to hormone treatment.

Cyclone is a portable gene-switch system that uses acyclovir to reversibly control gene expression with minimal toxicity.